Abstract | OBJECTIVE: PATIENTS AND METHODS: One-hundred and thirty-five patients with symptomatic urodynamically confirmed obstructive BPH were treated for 12 weeks with either doxazosin (67 patients) or placebo (68 patients) after an initial 2 week baseline evaluation. The main outcome measures were urodynamic and symptomatic evaluation for efficacy. Blood pressure and adverse events were monitored. RESULTS: Data were obtained in 122 patients (60 doxazosin, 62 placebo). Doxazosin produced increases in both mean and maximum urinary flow rates of 1.01 ml/s and 3.2 ml/s respectively, compared with 0.21 ml/s and 2.2 ml/s on placebo. The increase in mean flow rate was statistically significant (P = 0.04), while that for maximum flow rate approached significance (P = 0.09). The maximum subtracted voiding pressure was substantially reduced (P = 0.007) and 19 of 53 (36%) patients had an increase in maximum flow rate of 50% or more compared with 9 of 54 (17%) on placebo (P = 0.024). Twelve weeks' therapy with doxazosin resulted in significant improvements (compared with placebo) in: hesitancy ( doxazosin 26 of 46, placebo 11 of 43; P = 0.003), impaired urinary stream ( doxazosin 31 of 55, placebo 16 of 48; P = 0.019) nocturia ( doxazosin 22 of 56, placebo 10 of 54; P = 0.017) and urgency ( doxazosin 27 of 45, placebo 16 of 42; P = 0.041). Frequency improved with doxazosin therapy ( doxazosin 26 of 59, placebo 15 of 55; P = 0.062). Adverse events, most frequently dizziness and headache, were usually mild and transient and led to a discontinuation of doxazosin therapy in one patient. No clinically significant changes in sexual function or blood pressure were seen. CONCLUSION:
Doxazosin was well-tolerated and produced both urodynamic and symptomatic improvement in men with BPH, thereby providing a satisfactory alternative to existing drugs with the additional benefit of once daily dosage.
|
Authors | C R Chapple, P Carter, T J Christmas, R S Kirby, J Bryan, E J Milroy, P Abrams |
Journal | British journal of urology
(Br J Urol)
Vol. 74
Issue 1
Pg. 50-6
(Jul 1994)
ISSN: 0007-1331 [Print] England |
PMID | 7519112
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Aged
- Aged, 80 and over
- Double-Blind Method
- Doxazosin
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Prostatic Hyperplasia
(drug therapy, physiopathology)
- Treatment Outcome
- Urinary Bladder
(physiopathology)
- Urinary Bladder Neck Obstruction
(drug therapy, physiopathology)
- Urination
- Urodynamics
|